source
- FDA approves IntraBio's Aqneursa for rare ataxia-telangiectasia disorderFDA has granted approval for Aqneursa, a therapy developed by privately held biotech IntraBio, to treat ataxia-telangiectasia, a rare genetic disorder. The decision expands treatment options for pa…
- Novo outlines $23 billion 2035 revenue target, but investors react with a 7% share dropNovo’s chief executive used the recent Capital Markets Day to lay out a long‑term growth plan that targets $23 billion in annual sales by 2035. The strategy emphasizes expanding beyond its flagship…